2015
DOI: 10.4149/neo_2015_071
|View full text |Cite
|
Sign up to set email alerts
|

Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer

Abstract: Receptor-interacting protein kinase 3 (RIP3) is a member of the RIP Ser/Thr kinase family, plays an important role in regulating cell survival, cell apoptosis and cell necrosis. However, the role of RIP3 in the carcinogenesis of colorectal cancer is still poorly understood.We used quantitative PCR and Western blot analysis to examine RIP3 expression in primary colorectal cancer and paired normal colorectal mucosa. RIP3 clinicopathological significance was assessed by immunohistochemical staining in 112 cases o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
114
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 138 publications
(123 citation statements)
references
References 28 publications
4
114
0
Order By: Relevance
“…These findings correlate with observations that most cancer cell lines commonly used in the laboratory do not express RIPK3, which in response to chemotherapeutics represses programmed necrosis [27]. Moreover, overexpression of RIPK3 has been reported to suppress proliferation, migration and invasion of CRC cell lines [26]. These results support the idea that RIPK3 is critical in CRC as its expression might improve response to chemotherapy, and limit colorectal tumor initiation and progression.…”
Section: Introductionsupporting
confidence: 86%
See 1 more Smart Citation
“…These findings correlate with observations that most cancer cell lines commonly used in the laboratory do not express RIPK3, which in response to chemotherapeutics represses programmed necrosis [27]. Moreover, overexpression of RIPK3 has been reported to suppress proliferation, migration and invasion of CRC cell lines [26]. These results support the idea that RIPK3 is critical in CRC as its expression might improve response to chemotherapy, and limit colorectal tumor initiation and progression.…”
Section: Introductionsupporting
confidence: 86%
“…Lack of RIPK3 in these cells was found to impair nuclear translocation of NF-κB subunit RelB-p50 and caspase-1-mediated pro-IL-1β processing [25]. More recently, RIPK3 expression has been shown to be downregulated in human CRC tissues when compared to adjacent normal tissues [26]. These findings correlate with observations that most cancer cell lines commonly used in the laboratory do not express RIPK3, which in response to chemotherapeutics represses programmed necrosis [27].…”
Section: Introductionmentioning
confidence: 99%
“…Nonetheless, since proteasome inhibition has the capacity to activate RIPK3 and MLKL in leukemia cell lines, it will be interesting to determine whether bortezomib can induce necroptosis in primary leukemia cells. RIPK3 expression was found to be decreased in various human cancer cell lines (23,43) as well as in primary colon cancer (23,44), breast cancer (45), and acute myeloid leukemia (46). Development of drugs to re-activate expression of RIPK3 in cancer cells may therefore synergize with proteasome inhibitors to enhance cancer cell death and treatment efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…In a cohort of 112 patients with colorectal carcinoma, malignant cells exhibited reduced RIPK3 levels as compared with normal adjacent cells, and low RIPK3 expression constituted an independent prognostic factor for overall survival and disease-free survival (193, 194). Along similar lines, CD34 + blasts from 31 acute myeloid leukemia patients exhibited reduced levels of the RIPK3-coding mRNA as compared with CD34 + cells from healthy volunteers (195).…”
Section: Pathophysiological Relevance Of Necroptosismentioning
confidence: 99%